Genmab A/S
GMAB
$25.10
$0.301.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 26.33% | 26.33% | 28.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 26.33% | 26.33% | 28.98% |
| Cost of Revenue | -- | -- | 126.93% | 126.93% | 173.05% |
| Gross Profit | -- | -- | 23.14% | 23.14% | 25.58% |
| SG&A Expenses | -- | -- | 15.41% | 15.41% | 14.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 20.98% | 20.98% | 26.79% |
| Operating Income | -- | -- | 37.83% | 37.83% | 33.63% |
| Income Before Tax | -- | -- | 35.08% | 35.08% | 31.63% |
| Income Tax Expenses | -- | -- | -37.83% | -37.83% | -17.04% |
| Earnings from Continuing Operations | -- | -- | 61.17% | 61.17% | 46.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 61.17% | 61.17% | 46.06% |
| EBIT | -- | -- | 37.83% | 37.83% | 33.63% |
| EBITDA | -- | -- | 37.28% | 37.28% | 33.77% |
| EPS Basic | -- | -- | 66.02% | 66.02% | 49.45% |
| Normalized Basic EPS | -- | -- | 32.00% | 32.00% | 30.51% |
| EPS Diluted | -- | -- | 66.18% | 66.18% | 49.55% |
| Normalized Diluted EPS | -- | -- | 32.16% | 32.16% | 30.64% |
| Average Basic Shares Outstanding | -- | -- | -2.86% | -2.86% | -2.13% |
| Average Diluted Shares Outstanding | -- | -- | -3.06% | -3.06% | -2.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |